FDA announces recall of Tyco ReliOn single-use syringes
ROCKVILLE, Md. Food and Drug Administration said Wednesday that Tyco Healthcare Group is recalling a lot of its ReliOn single-use syringes for diabetics.
The recall affects lot number 813900, which contines 100 31-gauge ReliOn hypodermic syringes containing 1 milliliter of U-100 insulin. Tyco distributed 4,710 boxes in the recalled lot, totaling 471,000 individual syringes. Wal-Mart sold the syringes at its stores between Aug. 1 and Oct. 8, and Tyco voluntarily recalled the lot Oct. 9. Wal-Mart has sent letters to 16,500 customers notifying them of the recall and posted an announcement on its Web site.
Can-Am Care distributes the syringes and sells them through Wal-Mart and Sam?s Club stores under the Reli-On brand. The mass-merchandiser has requested that all users of this type of syringe return those that come from the recalled lot.
The FDA said that during the packaging of the syringes, some syringes labeled for use with U-40 insulin were mixed with syringes labeled for use with U-100 insulin and then packaged individually and in boxes as 100 units for use with U-100 insulin. Tyco has received one report of complications due to use of a syringe from the recalled lot.
AHIMA applauds Barack Obama for campaign success
CHICAGO The American Health Information Management Association has congratulated Barack Obama on his election as president of the United States, calling for reform of the healthcare system.
“Given the president-elect’s strong statements in support of health information as a key to expanding healthcare coverage while improving quality and controlling costs‹most recently during his infomercial last week—AHIMA is understandably optimistic,” AHIMA chief executive officer Linda Kloss said in a statement. “We urge the Obama administration to pursue the imperative of a 21st century health information platform that offers providers, payers and patients the accurate, integrated and secure electronic information they need to make decisions of utmost importance.”
GlaxoSmithKline consolidates U.S. headquarters, announces layoffs of 1,000
PHILADELPHIA GlaxoSmithKline, the maker of Abreva, Aquafresh toothpastes, Nicorette, Sensodyne and Tums will cut its workforce by about 1,800 jobs and make Research Triangle Park in North Carolina its permanent North American headquarters, replacing the current U.S. headquarters in Philadelphia, reports said today.
GlaxoSmithKline has had duel headquarters in the United States since the merger between Glaxo Wellcome and SmithKline Beecham was finalized in 2000, The Wall Street Journal today reported.
Today, GSK said that it will cut 1,800 positions, laying off about 1,000 people and eliminating hundreds of vacant positions, reports said.
GSK’s global headquarters are in London. The company is currently in the midst of belt-tightening in many departments due to growing pressure from the quickly expanding generic drug market and a decline in drug sales.